PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32054342-13	2020	In conclusion, FEB exhibited a protective effect in sepsis-induced liver and kidney injuries most probably through its anti-inflammatory, antioxidant, and antiapoptotic properties and attenuating JNK signaling pathway secondary to its XO enzyme inhibitory activity.	febuxostat	15-18	mitogen-activated protein kinase 8	Rattus norvegicus	196-199
31748427-8	2020	Serum creatinine (s-Cr) and eGFR were significantly better after 6 months of febuxostat treatment compared with topiroxostat Cystatin-C was significantly lower after 6 months of febuxostat treatment compared with topiroxostat.	febuxostat	178-188	cystatin C	Homo sapiens	125-135
31677062-3	2020	We postulated that febuxostat, a novel xanthine oxidase inhibitor, could suppress the ER stress through upregulation of SIRT1 (silent mating type information regulation 2 homolog 1)-AMPK (AMP activated protein kinase)-HO-1 (heme oxygenase-1)/thioredoxin expression.	febuxostat	19-29	xanthine dehydrogenase	Mus musculus	39-55
31677062-3	2020	We postulated that febuxostat, a novel xanthine oxidase inhibitor, could suppress the ER stress through upregulation of SIRT1 (silent mating type information regulation 2 homolog 1)-AMPK (AMP activated protein kinase)-HO-1 (heme oxygenase-1)/thioredoxin expression.	febuxostat	19-29	sirtuin 1	Mus musculus	120-125
31677062-3	2020	We postulated that febuxostat, a novel xanthine oxidase inhibitor, could suppress the ER stress through upregulation of SIRT1 (silent mating type information regulation 2 homolog 1)-AMPK (AMP activated protein kinase)-HO-1 (heme oxygenase-1)/thioredoxin expression.	febuxostat	19-29	heme oxygenase 1	Mus musculus	224-241
31677062-3	2020	We postulated that febuxostat, a novel xanthine oxidase inhibitor, could suppress the ER stress through upregulation of SIRT1 (silent mating type information regulation 2 homolog 1)-AMPK (AMP activated protein kinase)-HO-1 (heme oxygenase-1)/thioredoxin expression.	febuxostat	19-29	thioredoxin 1	Mus musculus	242-253
31677062-8	2020	Inhibitory effect of febuxostat was mediated through upregulation of SIRT1-AMPK followed by induction of HO-1 and thioredoxin.	febuxostat	21-31	sirtuin 1	Mus musculus	69-74
31677062-8	2020	Inhibitory effect of febuxostat was mediated through upregulation of SIRT1-AMPK followed by induction of HO-1 and thioredoxin.	febuxostat	21-31	heme oxygenase 1	Mus musculus	105-125
31677062-9	2020	In animal model of UUO, febuxostat reduced the UUO-induced ER stress, which was abolished by pretreatment with SIRT1 inhibitor (sirtinol) and AMPK inhibitor (compound C).	febuxostat	24-34	sirtuin 1	Mus musculus	111-116
31972252-4	2020	These beneficial effects of nitrate on diabetic mice were abolished by PTIO (NO scavenger) treatment and significantly prevented by febuxostat (xanthine oxidoreductase inhibitor), demonstrating the central importance of NO in bioactivation of nitrate.	febuxostat	132-142	xanthine dehydrogenase	Mus musculus	144-167
31556223-1	2019	Xanthine oxidoreductase (XOR) inhibitors, such as allopurinol and febuxostat, inhibit the catalysis of serum uric acid (SUA) synthesis.	febuxostat	66-76	xanthine dehydrogenase	Homo sapiens	0-23
31965018-6	2020	Despite a similar hypouricemic effect of the XO inhibitors on blood UA level, febuxostat, but not allopurinol, significantly decreased hepatic XO activity and UA levels in the NASH model mice.	febuxostat	78-88	xanthine dehydrogenase	Mus musculus	143-145
31965018-8	2020	Furthermore, in NAFLD patients with hyperuricemia, treatment with febuxostat for 24 weeks decreased the serum UA level, accompanied by reductions in the serum levels of liver enzymes, alanine aminotransferase and aspartate aminotransferase.	febuxostat	66-76	glutamic--pyruvic transaminase	Homo sapiens	184-208
31754153-3	2019	In this study, we report that febuxostat, an inhibitor of XOR, suppressed NLRP3 inflammasome-mediated IL-1beta secretion and cell death by two mechanisms: in a mitochondrial ROS (mitoROS)-dependent and mitoROS-independent manner.	febuxostat	30-40	xanthine dehydrogenase	Homo sapiens	58-61
31754153-3	2019	In this study, we report that febuxostat, an inhibitor of XOR, suppressed NLRP3 inflammasome-mediated IL-1beta secretion and cell death by two mechanisms: in a mitochondrial ROS (mitoROS)-dependent and mitoROS-independent manner.	febuxostat	30-40	NLR family pyrin domain containing 3	Homo sapiens	74-79
31754153-3	2019	In this study, we report that febuxostat, an inhibitor of XOR, suppressed NLRP3 inflammasome-mediated IL-1beta secretion and cell death by two mechanisms: in a mitochondrial ROS (mitoROS)-dependent and mitoROS-independent manner.	febuxostat	30-40	interleukin 1 beta	Homo sapiens	102-110
31882426-7	2019	However, febuxostat treatment also decreased URAT1 expression, whereas benzbromarone treatment increased its expression.	febuxostat	9-19	solute carrier family 22 (organic anion/cation transporter), member 12	Mus musculus	45-50
31560952-5	2019	Plasma and kidney xanthine oxidoreductase levels were decreased by febuxostat.	febuxostat	67-77	xanthine dehydrogenase	Mus musculus	18-41
31560952-8	2019	Furthermore, febuxostat enhanced AMPK phosphorylation and inhibited Nox1, Nox2, and HIF-1alpha expression in iohexol-exposed HK-2 cells.	febuxostat	13-23	NADPH oxidase 1	Mus musculus	68-72
31560952-8	2019	Furthermore, febuxostat enhanced AMPK phosphorylation and inhibited Nox1, Nox2, and HIF-1alpha expression in iohexol-exposed HK-2 cells.	febuxostat	13-23	cytochrome b-245, beta polypeptide	Mus musculus	74-78
31560952-8	2019	Furthermore, febuxostat enhanced AMPK phosphorylation and inhibited Nox1, Nox2, and HIF-1alpha expression in iohexol-exposed HK-2 cells.	febuxostat	13-23	hypoxia inducible factor 1, alpha subunit	Mus musculus	84-94
31546603-2	2019	Since DKD is the most common cause of end-stage renal disease, we investigated whether febuxostat, a xanthine oxidase (XO) inhibitor, exerts a protective effect against the development of DKD.	febuxostat	87-97	xanthine dehydrogenase	Mus musculus	101-117
31546603-2	2019	Since DKD is the most common cause of end-stage renal disease, we investigated whether febuxostat, a xanthine oxidase (XO) inhibitor, exerts a protective effect against the development of DKD.	febuxostat	87-97	xanthine dehydrogenase	Mus musculus	119-121
31546603-8	2019	Interestingly, the IL-1beta, IL-6, MCP-1, and ICAM-1 mRNA levels, which were increased in KK-Ay mouse kidneys as compared with normal controls, were suppressed by febuxostat administration.	febuxostat	163-173	interleukin 1 beta	Mus musculus	19-27
31546603-8	2019	Interestingly, the IL-1beta, IL-6, MCP-1, and ICAM-1 mRNA levels, which were increased in KK-Ay mouse kidneys as compared with normal controls, were suppressed by febuxostat administration.	febuxostat	163-173	interleukin 6	Mus musculus	29-33
31546603-8	2019	Interestingly, the IL-1beta, IL-6, MCP-1, and ICAM-1 mRNA levels, which were increased in KK-Ay mouse kidneys as compared with normal controls, were suppressed by febuxostat administration.	febuxostat	163-173	mast cell protease 1	Mus musculus	35-40
31546603-8	2019	Interestingly, the IL-1beta, IL-6, MCP-1, and ICAM-1 mRNA levels, which were increased in KK-Ay mouse kidneys as compared with normal controls, were suppressed by febuxostat administration.	febuxostat	163-173	intercellular adhesion molecule 1	Mus musculus	46-52